JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akamatsu, M.
Right arrow Articles by Kioka, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akamatsu, M.
Right arrow Articles by Kioka, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 50, 35933-35937, December 10, 1999


Vinexin Forms a Signaling Complex with Sos and Modulates Epidermal Growth Factor-induced c-Jun N-terminal Kinase/Stress-activated Protein Kinase Activities*

Masahiko Akamatsu, Shin-ichi AotaDagger , Akira Suwa, Kazumitsu Ueda, Teruo Amachi, Kenneth M. Yamada§, Steven K. Akiyama, and Noriyuki Kioka||

From the Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Sakyo-ku, Kyoto 606-8502, the Dagger  Biomolecular Engineering Research Institute, Suita, Osaka 565, Japan, the § Craniofacial Developmental Biology and Regeneration Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892, and the  Laboratory of Molecular Carcinogenesis, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Vinexin, a novel protein that plays a key role in cell spreading and cytoskeletal organization, contains three SH3 domains and binds to vinculin through its first and second SH3 domains. We show here that the third SH3 domain binds to Sos, a guanine nucleotide exchange factor for Ras and Rac, both in vitro and in vivo. Point mutations in the third SH3 domain abolished the vinexin-Sos interaction. Stimulation of NIH/3T3 cells with serum, epidermal growth factor (EGF), or platelet-derived growth factor (PDGF) decreased the electrophoretic mobility of Sos and concomitantly inhibited formation of the vinexin-Sos complex. Phosphatase treatment of lysates restored the binding of Sos to vinexin, suggesting that signaling from serum, EGF, or PDGF regulates the vinexin-Sos complex through the Sos phosphorylation. To evaluate the function of vinexin downstream of growth factors, we examined the effects of wild-type and mutant vinexin expression on extracellular signal-regulated kinase (Erk) and c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activation in response to EGF. Exogenous expression of vinexin beta  in NIH/3T3 cells enhanced JNK/SAPK activation but did not affect Erk activation. Moreover mutations in the third SH3 domain abolished EGF activation of JNK/SAPK in a dominant-negative fashion, whereas they slightly stimulated Erk. Together these results suggest that vinexin can selectively modulate EGF-induced signal transduction pathways leading to JNK/SAPK kinase activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The cell-extracellular matrix adherens junctions, also known as focal adhesions, play crucial roles in various aspects of cell behavior, including cell motility, cell proliferation, and cell differentiation. Focal adhesions are composed of transmembrane integrin cell adhesion receptors, the termini of actin stress fibers, as well as membrane-cytoskeletal linking and signaling proteins including vinculin, talin, alpha -actinin, and paxillin, which link the actin cytoskeleton to the cell adhesion molecules (1-3).

Growth factor receptors can associate with integrins (4, 5), and signaling molecules involved in growth factor-mediated pathways have also been shown to localize at or be associated with focal adhesions. For example, receptors for basic fibroblast growth factor, platelet-derived growth factor (PDGF),1 and epidermal growth factor (EGF) as well as downstream molecules including Sos, Raf, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), Erk, and JNK are localized at focal adhesions or fibronectin-induced adhesion complexes (6, 7). Moreover, signals from growth factors and the cell adhesion/cytoskeletal complex are well coordinated. Growth factor signaling can modulate cell motility and the cytoskeleton (8, 9). Conversely cell adhesion can enhance growth factor signaling (10-13) as well as stimulate the ligand-independent tyrosine phosphorylation of growth factor receptors (14, 15). Thus, there is substantial evidence for the cooperative function of cell adhesion and growth factor-mediated signaling. However, the molecular mechanisms of these types of cooperation are not fully understood.

Sos is one of the important signaling molecules recruited into focal adhesions (6). Sos has activity as a guanine nucleotide exchange factor (GEF) for Ras, and it mediates growth factor signals to the Erk kinase cascade leading to mitogenesis (16-23). Sos is composed of multiple functional domains, including a Dbl homology domain, a pleckstrin homology domain, a Ras GEF domain, and a C-terminal proline-rich domain. The proline-rich domain is a binding site for the SH3 (Src homology 3) domains of adaptor proteins such as Grb2, Nck, and CrkII, and it mediates the intracellular translocation of Sos in response to growth factors (24-26). The Dbl homology domain of Sos1 has been reported to have a GEF activity for another small GTPase Rac and to stimulate its downstream kinase, JNK/SAPK (27). Since Rac is thought to regulate cytoskeletal reorganization, Sos may play important roles in coordinated signaling involving both growth control and cytoskeletal organization (27).

Vinexin is a novel vinculin-binding protein localized at focal adhesion and cell-cell junctions (28). Expression of vinexin enhances actin cytoskeletal organization and cell spreading. Vinexin is transcribed into at least two alternative forms, vinexin alpha  and beta , both of which contain three SH3 domains. The first and second SH3 domains mediate the vinculin binding, whereas the binding partners of the third SH3 domain are unknown. Two closely related proteins, CAP/ponsin/SH3P12 and ArgBP2, have been identified. CAP/ponsin/SH3P12 also binds to vinculin as well as to other signaling molecules such as c-Cbl, insulin receptor, AF-6/afadin, and Sos, and it localizes at cell-cell and cell-matrix junctions (29-32). ArgBP2 binds to the Abelson protein tyrosine kinases, Arg and c-Abl, and localizes along stress fibers (33). These data suggest that this protein family may function in the coordinated regulation of signaling and the cytoskeleton, although such putative functions in signaling pathways are unclear.

Vinexin beta  has the most characteristic features of this protein family. Most of vinexin beta  is occupied by three SH3 domains, and no apparent enzymatic domains have been identified so far (28). This feature is similar to those of other adaptor or scaffold proteins, such as Grb2, Crk, and p130cas (34-36). It raises the possibility that vinexin beta  could function as a modulator of signal pathways. In the present study, we report that vinexin binds to Sos in vitro and in vivo, and this binding is mediated by the third SH3 domain of vinexin. Serum- and growth factor-induced Sos phosphorylation inhibited the formation of this vinexin-Sos complex. Furthermore, we found that vinexin modulated EGF-induced JNK/SAPK activation, in a process again dependent on the third SH3 domain of vinexin. These results indicate that vinexin beta  associates with Sos and that it can regulate JNK/SAPK MAP kinase cascades induced by EGF.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Monoclonal antibody (mAb) directed against Sos1 was obtained from Transduction Laboratories (Lexington, KY). Anti-FLAG epitope monoclonal antibody (mAb M2), anti-HA epitope monoclonal antibody (mAb 12CA5), and anti-phospho-Erk MAP kinase antibody were obtained from Eastman Kodak Co., Babco (Richmond, CA), and New England Biolabs, Inc. (Beverly, MA), respectively. Plasmids containing HA-JNK/SAPK and pGST-c-Jun were generous gifts from Dr. Eisuke Nishida (Kyoto University).

Generation of GST Fusion Proteins-- The GST fusion proteins containing vinexin domains, GST-1stSH3, GST-2ndSH3, and GST-1st2ndSH3, were described previously (28). The third SH3 domain of vinexin was amplified by polymerase chain reaction and subcloned into pGEX 4T-1 (Amersham Pharmacia Biotech) and was designated pGST-3rdSH3. Two mutants of the third SH3 domain were generated by substitutions at two of the most conserved amino acids among the SH3 domains (37). The mutations were introduced by using the Sculptor in vitro mutagenesis system (Amersham Pharmacia Biotech). The oligonucleotides 5'-CGATGGCTTCTTTGTGGG-3' and 5'-CCTGGAAATGTTGTAGCCC-3' were used for the mutations of the tryptophan residue at position 306 of vinexin beta  to phenylalanine (mutant WF) and the tyrosine residue at position 324 to valine (mutant YV), respectively. The mutations were confirmed by DNA sequencing. GST fusion proteins were purified as described (28).

In Vitro Binding Assays Using Affinity Precipitation-- NIH/3T3 fibroblast cells were incubated for 24 h in medium containing 0.5% calf serum. The cells were then stimulated with EGF (100 ng/ml), PDGF (20 ng/ml) (Sigma), or 20% calf serum for 10 or 60 min, followed by lysis in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1.0% Triton X-100, 1 mM sodium orthovanadate, 100 mM NaF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. The cell lysates were affinity precipitated with 5 µg of the GST fusion proteins for 3 h as described (28). Coprecipitated proteins were detected with the indicated specific antibodies and visualized using the ECL detection system (Amersham Pharmacia Biotech).

Phosphatase treatment was performed as follows. Cells were lysed in 30 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1.0% Triton X-100, 1 mM MgCl2, 0.1 mM ZnCl2, 10 µg/ml aprotinin, 1 µg/ml pepstatin, 5 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride (PMSF). The lysates (20 µg) in 200 µl were incubated with or without calf intestinal alkaline phosphatase (400 units, Takara Shuzo Co., Japan) for 1 h at 37 °C and then used for in vitro binding assays as described above.

Immunoprecipitation-- The expression plasmid for FLAG-tagged vinexin beta  was described previously (28). Two mutants (mutant WF and YV) in the third SH3 domain of FLAG-tagged vinexin beta  were generated as described above. These plasmids were transfected into NIH/3T3 cells with LipofectAMINE (Life Technologies, Inc.). Transfected cells were stimulated with serum and growth factors and lysed as described above. Equal amounts of total protein were incubated with 5 µg of anti-FLAG mAb M2 for 1 h at 4 °C. The immune complexes were incubated with protein G-Sepharose (Sigma) for 1 h and then precipitated and washed extensively with lysis buffer. The bound proteins were analyzed as described above.

ERK Kinase Assay-- ERK2 kinase activities were measured using anti-active ERK (anti-phospho-ERK) antibody. The expression plasmid for HA epitope-tagged Erk2 (38) was transfected into NIH/3T3 cells with or without FLAG-tagged vinexin beta . Transfected cells were serum-starved and were stimulated with 100 ng/ml EGF. Cells were then solubilized at 4 °C in lysis buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1.0% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM sodium vanadate, 50 mM NaF, 1 mM PMSF, 20 nM calyculin A, 20 µg/ml aprotinin, 20 µg/ml leupeptin, 5 mM benzamidine, and 40 mM beta -glycerophosphate. HA epitope-tagged Erk2 kinases were immunoprecipitated with mAb 12CA5 and were analyzed by immunoblotting using anti-active ERK antibody.

JNK/SAPK Assay-- JNK/SAPK activities were measured in an immune complex kinase assay as described (39) with minor modifications. Briefly, cells were solubilized as described above. The lysates were clarified by centrifugation. HA epitope-tagged JNK/SAPKs were immunoprecipitated with mAb 12CA5. The immunoprecipitates were resuspended in 30 µl of kinase reaction mixture containing 12.5 mM MOPS (pH 7.5), 12.5 mM beta -glycerophosphate, 7.5 mM MgCl2, 0.5 mM sodium orthovanadate, 3.3 mM dithiothreitol, 2 µg GST-c-Jun, 20 µM ATP, and 5 µCi of [gamma -32P]ATP. After incubation at 30 °C for 20 min, kinase reaction products were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and autoradiography. Quantitation was performed using an image analyzer BAS2000 (Fuji Photo Film Co., Japan).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interaction of the Third SH3 Domain of Vinexin with Sos-- The proline-rich domain of Sos is the binding site for the SH3 domains of several adaptor proteins including those of Grb2, Nck, and CrkII. A novel cytoskeletal protein, vinexin beta , consists of three SH3 domains with no apparent enzymatic feature so far, raising the possibility that vinexin beta  may be an adaptor protein and bind to Sos. To examine the interaction of vinexin with Sos in vitro, various SH3 domains of vinexin were expressed and purified as GST fusion proteins (Fig. 1, A, B, and D). These GST fusion proteins, bound to glutathione beads, were incubated with cell lysates prepared from NIH/3T3 cells. The bound proteins were analyzed by immunoblotting using an anti-Sos1 mAb. As shown in Fig. 1C, the third SH3 domain of vinexin bound to Sos, whereas the first and second SH3 domains did not bind. A GST fusion protein containing both the first and second SH3 domains, a minimal vinculin binding region (28), also did not bind to Sos. These results suggested that the third SH3 domain of vinexin specifically binds to Sos.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   In vitro association of the third SH3 domain of vinexin beta  with Sos. A, a schematic diagram of the vinexin deletion constructs. The numbered boxes indicate the SH3 domains. B, Coomassie Brilliant Blue (CBB) staining of purified GST fusion proteins described in A. C, cell lysates from NIH/3T3 cells were incubated with GST fusion proteins and glutathione-Sepharose beads. The precipitates were washed and resolved by 5% SDS-PAGE and then immunoblotted with anti-Sos1 mAb. D, Coomassie Brilliant Blue staining of GST fusion proteins containing the wild-type or mutated (WF, YV) third SH3 domain of vinexin (see "Experimental Procedures"). E, cell lysates from NIH/3T3 cells were incubated with the GST fusion proteins described in D. The precipitates were analyzed by immunoblotting using anti-Sos1 mAb. The GST fusion protein corresponding to each lane is indicated along the top.

To confirm the specificity of binding of the third SH3 domain of vinexin to Sos, we mutated the tryptophan residue at position 306 of the third SH3 domain of vinexin beta  to phenylalanine (WF mutant) or the tyrosine residue at position 324 to valine (YV mutant) to disrupt function of the SH3 domain. These residues are highly conserved in various SH3 domains and have been shown to be required for binding to proline-rich sequences (37). Both GST fusion proteins with either of these mutated third SH3 domains completely lost Sos-binding ability (Fig. 1E), indicating that the third SH3 domain of vinexin specifically interacts with Sos.

Previous studies have demonstrated that growth factor stimulation results in the feedback serine/threonine phosphorylation of Sos, with concomitant dissociation of the complex between Sos and adaptor proteins (17, 40-42), or that between Sos/Grb2 and receptor tyrosine kinase (43). To examine whether growth factor stimulation also modulates the affinity of Sos binding to vinexin, we first stimulated NIH/3T3 cells with 20% calf serum. As shown in Fig. 2A, serum stimulation decreased the electrophoretic mobility of Sos and concomitantly destabilized the complex between the third SH3 domain of vinexin and Sos. The effects were relatively stable, with only a slight restoration and formation of vinexin-Sos complexes 60 min after serum stimulation (Fig. 2A). We next examined the effects of EGF and PDGF on formation of the complex of vinexin and Sos. Similar to serum stimulation, both EGF and PDGF stimulation of NIH/3T3 also decreased the electrophoretic mobility of Sos and the affinities of Sos to vinexin (Fig. 2B). These data demonstrated that serum, EGF, and PDGF all induce dissociation of the complex between vinexin and Sos.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Serum, EGF, and PDGF stimulation decrease the binding of Sos to vinexin. A, NIH/3T3 cells were serum-starved for 24 h and left untreated or were stimulated with calf serum for the indicated times. Lysates were either directly analyzed by SDS-PAGE or subjected to affinity precipitation with GST fusion proteins containing the third SH3 domain of vinexin beta . The precipitates were washed and analyzed by SDS-PAGE. Both gels were subjected to immunoblotting using anti-Sos1 mAb. B, cells were serum-starved for 24 h and left untreated or stimulated with calf serum, 100 ng/ml EGF, or 20 ng/ml PDGF for 10 min. Affinity precipitation and immunoblotting using anti-Sos1 mAb were performed as described in A.

Vinexin Interaction with Sos and Down-regulation of the Interaction by Serum Stimulation in Vivo-- To determine whether the interaction between vinexin and Sos occurs in vivo, we transfected FLAG-tagged vinexin beta  with or without point mutations in the third SH3 domain or the vector alone into NIH/3T3 cells. Lysates prepared from transfected cells were immunoprecipitated with anti-FLAG mAb, and precipitates were evaluated by immunoblotting with anti-FLAG mAb or anti-Sos1 mAb. As shown in Fig. 3, Sos was coimmunoprecipitated with FLAG-tagged vinexin beta  but not from the lysates transfected by vector alone. Sos was also not precipitated with mutated FLAG-tagged vinexin beta  containing mutations in the third SH3 domain. Moreover, Sos was not coimmunoprecipitated from lysates of serum-stimulated cells transfected with FLAG-tagged vinexin beta . These data suggested that the third SH3 domain of vinexin binds to Sos in intact cells as well as in vitro and that the interaction is regulated by serum stimulation.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   In vivo association of vinexin beta  with Sos. NIH/3T3 cells were transfected with vector alone (p401F) or FLAG-tagged wild-type (w.t.) or mutated (WF, YV) vinexin beta . Following transfection, cells were serum-starved for 24 h and left untreated or stimulated with 20% calf serum for 10 min. Cell lysates (20 µg) were immunoblotted using anti-FLAG mAb to detect the transfected vinexin beta  (A) or anti-Sos1 mAb to confirm the expression and mobility shift of Sos (C). The remaining cell lysates (500 µg) were immunoprecipitated (IP) with anti-FLAG mAb. Immunocomplexes were subjected to immunoblotting using anti-FLAG mAb to confirm the precipitation of vinexin beta  (B), or using anti-Sos1 mAb to detect Sos that had coprecipitated with vinexin beta  (D).

Regulation of the Interaction between Vinexin and Sos by the Phosphorylation of Sos-- To determine whether the mobility shift of Sos and the interaction of vinexin with Sos are actually regulated by phosphorylation, serum-stimulated cell lysates were treated with alkaline phosphatase. Cell lysates incubated with or without alkaline phosphatase were precipitated with the GST fusion protein containing the third SH3 domain of vinexin. As shown in Fig. 4A, when lysates were treated with alkaline phosphatase, the serum-induced electrophoretic mobility shift was substantially reversed (Fig. 4A, lane 4, and Fig. 4B, lane 3). Similarly, the binding of Sos to vinexin was restored after the phosphatase treatment (lane 6). These data suggest that the phosphorylation of Sos following serum stimulation is required for the electrophoretic mobility shift, at least in part, and for the dissociation of the vinexin-Sos complex.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 4.   Phosphorylation of Sos inhibits the formation of the vinexin-Sos complex. NIH/3T3 cells were serum-starved and left untreated or stimulated with calf serum for 10 min. Cell lysates were incubated with or without calf intestinal alkaline phosphatase (CIP) at 37 °C for 1 h. Lysates were either directly analyzed by SDS-PAGE (A) or affinity precipitated with a GST fusion protein containing the third SH3 domain of vinexin beta  (B). Samples were resolved by SDS-PAGE and immunoblotted with anti-Sos1 mAb.

Effects of the Interaction between Vinexin and Sos on JNK/SAPK Activities-- Sos catalyzes the exchange of GDP to GTP on Ras and Rac (27). In the activated GTP-bound form, Ras and Rac activate several downstream targets, including Erk and JNK/SAPK, respectively (44-46). Therefore, we examined the effect of vinexin beta  expression on Erk2 and JNK/SAPK activation in response to EGF stimulation in NIH/3T3 cells. Cells were cotransfected with FLAG-tagged vinexin beta , FLAG-tagged mutated vinexin beta s, or the vector alone each with or without HA-tagged Erk2 or JNK/SAPK. Erk2 and JNK/SAPK activities were both stimulated by EGF. The highest activities were observed at 5 min for Erk2 and at 25 min for JNK/SAPK after EGF stimulation, when vector and HA-tagged kinases were cotransfected (data not shown). Therefore, the effects of overexpression of various forms of vinexin beta  were determined at these time points. Expression of vinexin beta  did not affect the Erk2 activation induced by EGF stimulation (data not shown). In contrast, expression of vinexin beta  enhanced JNK/SAPK activation in response to EGF stimulation as shown in Fig. 5. This effect was specific to wild-type vinexin beta , and no activation was observed in cells transfected by mutated vinexin beta . In fact, transfection with mutated vinexin beta  had marked dominant-negative effects in blocking most of the JNK/SAPK response to EGF (Fig. 5B), although expression of mutated vinexin beta  appeared to enhance the Erk activation slightly (data not shown). Enhancement of EGF-induced JNK/SAPK activation by expression of wild-type vinexin beta  and dominant-negative effects by expression of mutated vinexin beta  were also observed in COS-7 cells (data not shown). These results suggest that vinexin beta  is involved in the activation of JNK/SAPK in response to EGF and that the third SH3 domain of vinexin beta  is important for this stimulation.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of vinexin beta  transfection on EGF-induced JNK/SAPK activity. NIH/3T3 cells were cotransfected with vector alone (p401F) or vinexin beta  (w.t., WF, or YV) together with or without HA-tagged JNK/SAPK. Cells were then serum-starved and left untreated or stimulated with 100 ng/ml EGF for 25 min. A, lysates (20 µg) were directly immunoblotted with anti-HA mAb (top panel) or anti-FLAG mAb (middle panel) to verify the expression of HA-JNK/SAPK and FLAG-vinexin beta  constructs, respectively. The remaining lysates (200 µg) were immunoprecipitated with anti-HA mAb, and the immunocomplexes were subjected to JNK/SAPK kinase assay using GST-c-Jun as a substrate. The phosphorylated substrates were resolved by SDS-PAGE and visualized by autoradiography (bottom panel). B, values correspond to the average of duplicate points and are expressed as -fold increase with respect to vector-transfected cells (p401F) without EGF stimulation. Error bars correspond to the range of values. The representative of two independent experiments is shown.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have recently identified vinexin as a novel focal adhesion protein, which plays a role in cytoskeletal organization and cell spreading (28). Vinexin contains three SH3 domains. The first two SH3 domains are important for vinculin binding. In the present study, we show that the third SH3 domain of vinexin associates with Sos, a guanine nucleotide exchange factor for Ras and Rac, both in vitro and in vivo. Serum, PDGF, and EGF treatment induced dissociation of the vinexin-Sos complex by phosphorylating Sos. Moreover, expression of vinexin beta  in NIH/3T3 and COS-7 cells promoted JNK/SAPK activation in response to EGF. Vinexin molecules with point mutations in the third SH3 domain displayed potent dominant-negative activity in suppression of the JNK/SAPK response to EGF. Together these results indicate that vinexin modulates not only cytoskeleton/cell spreading but also signal transduction induced by EGF and other growth factors.

We presented evidence that vinexin bound to Sos both in vitro and in vivo. We also showed that the binding site of vinexin for Sos was the third SH3 domain by using deletion mutants and point mutations in the third SH3 domain. The point mutations utilized here have been reported to disrupt the function but not the structure of SH3 domains (37), suggesting that the loss of Sos-binding ability is derived from the loss of SH3 function and not an artifact of structural alteration.

The exact binding site in Sos for vinexin remains to be determined, although the C-terminal proline-rich domain of Sos is the most plausible, because other SH3-containing adaptor molecules are known to bind in that region (24-26). It is also intriguing that the minimal vinculin-binding region of vinexin, the first and second SH3 domains, is not necessary for Sos binding. This result suggests that a ternary complex of vinculin-vinexin-Sos may form a functional unit.

Serum-, EGF-, and PDGF-initiated signal transduction all regulated the affinity of Sos to vinexin by regulating Sos phosphorylation. Several lines of evidence have shown that serum or other growth factors can modulate Sos phosphorylation through Erk or other kinases and result in the dissociation of the adaptor-Sos complex (17, 40-43, 47-49). In these cases, phosphorylation and subsequent dissociation of the complex are thought to provide negative feedback regulation for Ras and downstream signaling. The time course of dissociation of the vinexin-Sos complex was consistent with those of other adaptor-Sos complexes. These observations suggest that vinexin might also be involved in the regulation of signals initiated by receptor tyrosine kinases culminating in downstream MAP kinase activation.

Vinexin enhanced the activation of JNK/SAPK in response to EGF. Mutations in the third SH3 domain that abolished the ability of vinexin to bind to Sos eliminated this effect. Most importantly, both of these mutations were capable of functioning as "dominant-negative" inhibitors that strongly suppressed EGF-mediated JNK/SAPK activation in both NIH/3T3 and COS-7 cells. These findings indicate that vinexin regulates the signaling pathway from EGF stimulation to JNK/SAPK activation using its third SH3 domain. Although the precise role of vinexin in JNK/SAPK activation is not clear, it is possible that vinexin is required to recruit Sos to focal adhesions into close proximity to other signaling molecules and that this bound Sos activates Rac, leading to JNK/SAPK activation (27, 45, 46). Recently human vinexin alpha  (GenBankTM accession number AF037261) was reported in the GenBankTM data base to bind to PAK, an effector of Rac. Therefore, it is also possible that vinexin functions as a scaffold protein that binds to vinculin, Sos, PAK, and other molecules.

In conclusion, we have found that vinexin binds not only to the cytoskeletal protein vinculin but also to the signaling molecule Sos. Vinexin is involved in the signaling from EGF to JNK/SAPK MAP kinase, as well as in the regulation of cytoskeleton/cell spreading.

    ACKNOWLEDGEMENT

We thank Dr. Eisuke Nishida (Kyoto University) for the gift of plasmids for HA-JNK/SAPK and GST-c-Jun.

    FOOTNOTES

* This work was supported in part by The Agricultural Chemical Research Foundation, the Sasakawa Scientific Research Grant from The Japan Society, Nestlé Science Promotion Committee, and a grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: the Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Sakyo-ku, Kyoto 606-8502, Japan. Fax: 81-75-753-6104; E-mail: nkioka@kais.kyoto-u.ac.jp.

    ABBREVIATIONS

The abbreviations used are: PDGF, platelet-derived growth factor; EGF, epidermal growth factor; GEF, guanine nucleotide exchange factor; SH3, Src homology 3; mAb, monoclonal antibody; GST, glutathione S-transferase; ERK, extracellular signal-regulated protein kinase; JNK, c-Jun N-terminal kinase; SAPK, stress-activated protein kinase; PAGE, polyacrylamide gel electrophoresis; HA, hemagglutinin; MOPS, 4-morpholinepropanesulfonic acid; MAP, mitogen-activated protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Burridge, K., and Fath, K. (1989) BioEssays 10, 104-108[CrossRef][Medline] [Order article via Infotrieve]
2. Jockusch, B. M., Bubeck, P., Giehl, K., Kroemker, M., Moschner, J., Rothkegel, M., Rudiger, M., Schluter, K., Stanke, G., and Winkler, J. (1995) Annu. Rev. Cell Dev. Biol. 11, 379-416[CrossRef][Medline] [Order article via Infotrieve]
3. Yamada, K. M., and Geiger, B. (1997) Curr. Opin. Cell Biol. 9, 76-85[CrossRef][Medline] [Order article via Infotrieve]
4. Schneller, M., Vuori, K., and Ruoslahti, E. (1997) EMBO J. 16, 5600-5607[CrossRef][Medline] [Order article via Infotrieve]
5. Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G., and Bussolino, F. (1999) EMBO J. 18, 882-892[CrossRef][Medline] [Order article via Infotrieve]
6. Miyamoto, S., Teramoto, H., Coso, O. A., Gutkind, J. S., Burbelo, P. D., Akiyama, S. K., and Yamada, K. M. (1995) J. Cell Biol. 131, 791-805[Abstract/Free Full Text]
7. Plopper, G. E., McNamee, H. P., Dike, L. E., Bojanowski, K., and Ingber, D. E. (1995) Mol. Biol. Cell 6, 1349-1365[Abstract]
8. Klemke, R. L., Yebra, M., Bayna, E. M., and Cheresh, D. A. (1994) J. Cell Biol. 127, 859-866[Abstract/Free Full Text]
9. Mainiero, F., Pepe, A., Yeon, M., Ren, Y., and Giancotti, F. G. (1996) J. Cell Biol. 134, 241-253[Abstract/Free Full Text]
10. Vuori, K., and Ruoslahti, E. (1994) Science 266, 1576-1578[Abstract/Free Full Text]
11. Miyamoto, S., Teramoto, H., Gutkind, J. S., and Yamada, K. M. (1996) J. Cell Biol. 135, 1633-1642[Abstract/Free Full Text]
12. Lin, T. H., Chen, Q., Howe, A., and Juliano, R. L. (1997) J. Biol. Chem. 272, 8849-8852[Abstract/Free Full Text]
13. Renshaw, M. W., Ren, X. D., and Schwartz, M. A. (1997) EMBO J. 16, 5592-5599[CrossRef][Medline] [Order article via Infotrieve]
14. Sundberg, C., and Rubin, K. (1996) J. Cell Biol. 132, 741-752[Abstract/Free Full Text]
15. Moro, L., Venturino, M., Bozzo, C., Silengo, L., Altruda, F., Beguinot, L., Tarone, G., and Defilippi, P. (1998) EMBO J. 17, 6622-6632[CrossRef][Medline] [Order article via Infotrieve]
16. Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, R., Ullrich, A., Skolnik, E. Y., Bar-Sagi, D., and Schlessinger, J. (1992) Cell 70, 431-442[CrossRef][Medline] [Order article via Infotrieve]
17. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T., and Bowtell, D. (1993) Nature 363, 83-85[CrossRef][Medline] [Order article via Infotrieve]
18. Li, N., Batzer, A., Daly, R., Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis, B., and Schlessinger, J. (1993) Nature 363, 85-88[CrossRef][Medline] [Order article via Infotrieve]
19. Gale, N. W., Kaplan, S., Lowenstein, E. J., Schlessinger, J., and Bar-Sagi, D. (1993) Nature 363, 88-92[CrossRef][Medline] [Order article via Infotrieve]
20. Buday, L., and Downward, J. (1993) Cell 73, 611-620[CrossRef][Medline] [Order article via Infotrieve]
21. Chardin, P., Camonis, J. H., Gale, N. W., van Aelst, L., Schlessinger, J., Wigler, M. H., and Bar-Sagi, D. (1993) Science 260, 1338-1343[Abstract/Free Full Text]
22. Skolnik, E. Y., Batzer, A., Li, N., Lee, C. H., Lowenstein, E., Mohammadi, M., Margolis, B., and Schlessinger, J. (1993) Science 260, 1953-1955[Abstract/Free Full Text]
23. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. (1993) Nature 363, 45-51[CrossRef][Medline] [Order article via Infotrieve]
24. Hu, Q., Milfay, D., and Williams, L. T. (1995) Mol. Cell. Biol. 15, 1169-1174[Abstract]
25. Feller, S. M., Knudsen, B., and Hanafusa, H. (1995) Oncogene 10, 1465-1473[Medline] [Order article via Infotrieve]
26. Matsuda, M., Hashimoto, Y., Muroya, K., Hasegawa, H., Kurata, T., Tanaka, S., Nakamura, S., and Hattori, S. (1994) Mol. Cell. Biol. 14, 5495-5500[Abstract/Free Full Text]
27. Nimnual, A. S., Yatsula, B. A., and Bar-Sagi, D. (1998) Science 279, 560-563[Abstract/Free Full Text]
28. Kioka, N., Sakata, S., Kawauchi, T., Amachi, T., Akiyama, S. K., Okazaki, K., Yaen, C., Yamada, K. M., and Aota, S. (1999) J. Cell Biol. 144, 59-69[Abstract/Free Full Text]
29. Sparks, A. B., Hoffman, N. G., McConnell, S. J., Fowlkes, D. M., and Kay, B. K. (1996) Nat. Biotechnol. 14, 741-744[CrossRef][Medline] [Order article via Infotrieve]
30. Ribon, V., Herrera, R., Kay, B. K., and Saltiel, A. R. (1998) J. Biol. Chem. 273, 4073-4080[Abstract/Free Full Text]
31. Ribon, V., Printen, J. A., Hoffman, N. G., Kay, B. K., and Saltiel, A. R. (1998) Mol. Cell. Biol. 18, 872-879[Abstract/Free Full Text]
32. Mandai, K., Nakanishi, H., Satoh, A., Takahashi, K., Satoh, K., Nishioka, H., Mizoguchi, A., and Takai, Y. (1999) J. Cell Biol. 144, 1001-1018[Abstract/Free Full Text]
33. Wang, B., Golemis, E. A., and Kruh, G. D. (1997) J. Biol. Chem. 272, 17542-17550[Abstract/Free Full Text]
34. Feig, L. A. (1993) Science 260, 767-768[Free Full Text]
35. Feller, S. M., Ren, R., Hanafusa, H., and Baltimore, D. (1994) Trends Biochem. Sci. 19, 453-458[CrossRef][Medline] [Order article via Infotrieve]
36. Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994) EMBO J. 13, 3748-3756[Medline] [Order article via Infotrieve]
37. Lim, W. A., and Richards, F. M. (1994) Nat. Struct. Biol. 1, 221-225[CrossRef][Medline] [Order article via Infotrieve]
38. Gu, J., Tamura, M., and Yamada, K. M. (1998) J. Cell Biol. 143, 1375-1383[Abstract/Free Full Text]
39. Atfi, A., Djelloul, S., Chastre, E., Davis, R., and Gespach, C. (1997) J. Biol. Chem. 272, 1429-1432[Abstract/Free Full Text]
40. Waters, S. B., Yamauchi, K., and Pessin, J. E. (1995) Mol. Cell. Biol. 15, 2791-2799[Abstract]
41. Cherniack, A. D., Klarlund, J. K., Conway, B. R., and Czech, M. P. (1995) J. Biol. Chem. 270, 1485-1488[Abstract/Free Full Text]
42. Okada, S., and Pessin, J. E. (1996) J. Biol. Chem. 271, 25533-25538[Abstract/Free Full Text]
43. Porfiri, E., and McCormick, F. (1996) J. Biol. Chem. 271, 5871-5877[Abstract/Free Full Text]
44. Crews, C. M., and Erikson, R. L. (1993) Cell 74, 215-217[Medline] [Order article via Infotrieve]
45. Coso, O. A., Chiariello, M., Yu, J. C., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J. S. (1995) Cell 81, 1137-1146[CrossRef][Medline] [Order article via Infotrieve]
46. Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) Cell 81, 1147-1157[CrossRef][Medline] [Order article via Infotrieve]
47. Corbalan-Garcia, S., Yang, S. S., Degenhardt, K. R., and Bar-Sagi, D. (1996) Mol. Cell. Biol. 16, 5674-5682[Abstract]
48. Chen, D., Waters, S. B., Holt, K. H., and Pessin, J. E. (1996) J. Biol. Chem. 271, 6328-6332[Abstract/Free Full Text]
49. Zhao, H., Okada, S., Pessin, J. E., and Koretzky, G. A. (1998) J. Biol. Chem. 273, 12061-12067[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
GENES CELLSHome page
M. Mitsushima, K. Ueda, and N. Kioka
Vinexin beta regulates the phosphorylation of epidermal growth factor receptor on the cell surface.
Genes Cells, September 1, 2006; 11(9): 971 - 982.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
M. Mitsushima, T. Sezaki, R. Akahane, K. Ueda, S. Suetsugu, T. Takenawa, and N. Kioka
Protein kinase A-dependent increase in WAVE2 expression induced by the focal adhesion protein vinexin
Genes Cells, March 1, 2006; 11(3): 281 - 292.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
M. Matsuyama, H. Mizusaki, A. Shimono, T. Mukai, K. Okumura, K. Abe, K. Shimada, and K.-i. Morohashi
A novel isoform of Vinexin, Vinexin {gamma}, regulates Sox9 gene expression through activation of MAPK cascade in mouse fetal gonad
Genes Cells, May 1, 2005; 10(5): 421 - 434.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Bour, J.-L. Plassat, A. Bauer, S. Lalevee, and C. Rochette-Egly
Vinexin {beta} Interacts with the Non-phosphorylated AF-1 Domain of Retinoid Receptor {gamma} (RAR{gamma}) and Represses RAR{gamma}-mediated Transcription
J. Biol. Chem., April 29, 2005; 280(17): 17027 - 17037.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Mitsushima, A. Suwa, T. Amachi, K. Ueda, and N. Kioka
Extracellular Signal-regulated Kinase Activated by Epidermal Growth Factor and Cell Adhesion Interacts with and Phosphorylates Vinexin
J. Biol. Chem., August 13, 2004; 279(33): 34570 - 34577.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Munehira, T. Ohnishi, S. Kawamoto, A. Furuya, K. Shitara, M. Imamura, T. Yokota, S. Takeda, T. Amachi, M. Matsuo, et al.
{alpha}1-Syntrophin Modulates Turnover of ABCA1
J. Biol. Chem., April 9, 2004; 279(15): 15091 - 15095.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Tujague, J. S. Thomsen, K. Mizuki, C. M. Sadek, and J.-A. Gustafsson
The Focal Adhesion Protein Vinexin {alpha} Regulates the Phosphorylation and Activity of Estrogen Receptor {alpha}
J. Biol. Chem., March 5, 2004; 279(10): 9255 - 9263.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Wakabayashi, T. Ito, M. Mitsushima, S. Aizawa, K. Ueda, T. Amachi, and N. Kioka
Interaction of lp-dlg/KIAA0583, a Membrane-associated Guanylate Kinase Family Protein, with Vinexin and {beta}-Catenin at Sites of Cell-Cell Contact
J. Biol. Chem., June 6, 2003; 278(24): 21709 - 21714.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. Townson, K. M. Dobrzycka, A. V. Lee, M. Air, W. Deng, K. Kang, S. Jiang, N. Kioka, K. Michaelis, and S. Oesterreich
SAFB2, a New Scaffold Attachment Factor Homolog and Estrogen Receptor Corepressor
J. Biol. Chem., May 23, 2003; 278(22): 20059 - 20068.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Suwa, M. Mitsushima, T. Ito, M. Akamatsu, K. Ueda, T. Amachi, and N. Kioka
Vinexin beta Regulates the Anchorage Dependence of ERK2 Activation Stimulated by Epidermal Growth Factor
J. Biol. Chem., April 5, 2002; 277(15): 13053 - 13058.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akam